Testing effectiveness (Phase 2)Study completedNCT02034981
What this trial is testing
Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1
Who this might be right for
Hematologic CancersSolid TumorsMetastatic Cancer
UNICANCER 246